<table id="table9" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 9. Bioavailability of Divalproex Sodium Extended-Release Tablets Relative to Divalproex Sodium Delayed-Release Tablets When Divalproex Sodium Extended-Release Tablets Dose is 8 to 20% Higher</caption>
<col align="left" valign="top" width="20%"></col>
<col align="left" valign="top" width="50%"></col>
<col align="center" valign="top" width="10%"></col>
<col align="center" valign="top" width="10%"></col>
<col align="center" valign="top" width="10%"></col>
<thead>
<tr>
<th rowspan="2">Study Population</th>
<th>Regimens </th>
<th align="left" colspan="3">Relative Bioavailability</th>
</tr>
<tr>
<th>Divalproex Sodium Extended-Release Tablets vs. Divalproex Sodium Delayed-Release Tablets</th>
<th align="center">AUC<sub>24</sub>
</th>
<th>C<sub>max</sub>
</th>
<th>C<sub>min</sub>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthy Volunteers  (N=35)</td>
<td>1000 &amp; 1500 mg divalproex sodium extended-release tablets vs. 875 &amp; 1250 mg divalproex sodium delayed-release tablets</td>
<td>1.059</td>
<td>0.882</td>
<td>1.173</td>
</tr>
<tr>
<td>Patients with epilepsy on concomitant enzyme-inducing antiepilepsy drugs (N=64)</td>
<td>1000 to 5000 mg divalproex sodium extended-release tablets vs. 875 to 4250 mg divalproex sodium delayed-release tablets</td>
<td>1.008</td>
<td>0.899</td>
<td>1.022</td>
</tr>
</tbody>
</table>